AnDiConBio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series B1

  • Investors
  • 15

AnDiConBio General Information

Description

Developer of drugs designed for respiratory anti-infection. The company has established a product pipeline including a variety of drugs, including new anti-influenza and oral anti-new coronavirus, which have high drug potential and low clinical risks, thereby providing customers with safe and efficient drugs.

Contact Information

Website
www.andicon.cn
Formerly Known As
Antican (Wuxi) Biotechnology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 101, Building 13, Block 3, Number 382, Yatai Road
  • Daqiao Town, Nanhu District
  • Jiaxing, Zhejiang 900000
  • China
+86 0573
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Room 101, Building 13, Block 3, Number 382, Yatai Road
  • Daqiao Town, Nanhu District
  • Jiaxing, Zhejiang 900000
  • China
+86 0573

AnDiConBio Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnDiConBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B1) 15-Sep-2025 Completed Generating Revenue
4. Later Stage VC (Series A1) 30-Apr-2025 Completed Generating Revenue
3. Later Stage VC (Series A) 23-Apr-2024 Completed Generating Revenue
2. Later Stage VC 08-Nov-2023 $15.7M Completed Generating Revenue
1. Early Stage VC 09-Apr-2022 $15.7M $15.7M Completed Generating Revenue
To view AnDiConBio’s complete valuation and funding history, request access »

AnDiConBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AnDiConBio Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Heda Ventures Venture Capital Minority
Hengdian Capital Venture Investment (Zhejiang) Growth/Expansion Minority
HaiBang Ventures Venture Capital Minority
GSR United Capital Venture Capital Minority
Huajin Investment Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

AnDiConBio FAQs

  • When was AnDiConBio founded?

    AnDiConBio was founded in 2018.

  • Where is AnDiConBio headquartered?

    AnDiConBio is headquartered in Jiaxing, China.

  • What is the size of AnDiConBio?

    AnDiConBio has 6 total employees.

  • What industry is AnDiConBio in?

    AnDiConBio’s primary industry is Drug Discovery.

  • Is AnDiConBio a private or public company?

    AnDiConBio is a Private company.

  • What is AnDiConBio’s current revenue?

    The current revenue for AnDiConBio is .

  • How much funding has AnDiConBio raised over time?

    AnDiConBio has raised $43.4M.

  • Who are AnDiConBio’s investors?

    Heda Ventures, Hengdian Capital Venture Investment (Zhejiang), HaiBang Ventures, GSR United Capital, and Huajin Investment are 5 of 15 investors who have invested in AnDiConBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process